Join Clinical Trials
  • Login
  • Home
  • Clinical Trial Categories
  • Clinical Trials by Condition
  • Bb
  • B-cell Lymphoma


Menu

Choose Which Database to Search - Volunteer Database - Clinical Trial Database Create an Account - VOLUNTEER Accounts - RECRUITER Accounts Account Login - Volunteers Login - Recruiters Login Join a Clinical Trial Clinical Trials by Category Clinical Trials by Location Submit a Clinical Trial Frequently Asked Questions Contact Us Sitemap Blog

Categories

    Healthy Volunteers Adults - 18 - 64 Youths - Birth - 17 Seniors - 65 + Expanded Access Compensated Trials Clinical Trials by Condition Trials by Drug Type Trials for Rare Conditions

Recent Listings

  • Post your clinical trial on JoinClinicalTrials.com

    Ellijay, Georgia 30536
    United States

    Post your clinical trial on JoinClinicalTrials.com

    05-09-2019 01:01PM

JoinClinicalTrials.com





  • A Study of C-CAR066 in Subjects With r/r B Cell Lymphoma Who Received CD19 CAR-T Therapy
    NCT04036019
    Condition:   B Cell Lymphoma
    Intervention:   Biological: CD20-directed CAR-T cells
    Sponsors:   Shanghai Tongji Hospital, Tongji University School of Medicine;   Cellular Biomedicine Group Ltd.
    Recruiting
  • Microtransplantation and Checkpoint Blockade Immunotherapy for Relapsed or Refractory B Cell Lymphomas
    NCT03920631
    Condition:   B Cell Lymphomas
    Interventions:   Drug: Nivolumab;   Biological: Microtransplantation
    Sponsor:   Ahmed Galal, MD
    Recruiting
  • INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)
    NCT03424122
    Condition:   B-cell Lymphoma
    Interventions:   Drug: Parsaclisib;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Ibrutinib
    Sponsor:   Incyte Corporation
    Recruiting
  • Study of TG-1801 in Subjects With B-Cell Lymphoma
    NCT03804996
    Condition:   B-Cell Lymphoma
    Intervention:   Drug: TG-1801
    Sponsor:   TG Therapeutics, Inc.
    Recruiting
  • Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.
    NCT03929107
    Condition:   B Cell Lymphoma
    Intervention:   Biological: Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T cells
    Sponsors:   Wenbin Qian;   Zhejiang Provincial Tongde Hospital
    Recruiting
  • Efficacy and Safety of Axicabtagene Ciloleucel as First-Line Therapy in Participants With High-Risk Large B-Cell Lymphoma
    NCT03761056
    Condition:   B-cell Lymphoma
    Interventions:   Biological: Axicabtagene Ciloleucel;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Kite, A Gilead Company
    Recruiting
  • A Study to Investigate BGB-3111 in Chinese Patients With B-cell Lymphoma
    NCT03189524
    Condition:   B-cell Lymphoma
    Intervention:   Drug: BGB-3111
    Sponsor:   BeiGene
    Recruiting
  • A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients
    NCT03670888
    Condition:   B Cell Lymphoma
    Interventions:   Biological: JHL1101;   Biological: Rituximab
    Sponsor:   JHL Biotech, Inc.
    Not yet recruiting
  • Cell Free DNA in Mature B-cell Lymphoma
    NCT04088422
    Condition:   Mature B-Cell Lymphoma
    Intervention:   Procedure: peripheral blood collection
    Sponsor:   Ruijin Hospital
    Recruiting
  • A Phase Ib Study of Oral Selinexor in Adult Patients With Relapsed/Refractory B-cell Lymphoma Receiving R-DHAOx or R-GDP
    NCT02741388
    Condition:   B-cell Lymphoma
    Interventions:   Drug: selinexor;   Drug: Rituximab;   Drug: Dexamethasone;   Drug: Oxaliplatin;   Drug: Cisplatin;   Drug: Cytarabine;   Drug: Gemcitabine
    Sponsors:   The Lymphoma Academic Research Organisation;   Karyopharm Therapeutics Inc
    Recruiting
  • Study of Anti-CD19 iCAR NK Cells in Relapsed and Refractory B Cell Lymphoma
    NCT03824951
    Condition:   Refractory B-Cell Lymphoma
    Intervention:   Biological: Anti-CD19 iCAR NK Cells
    Sponsors:   Allife Medical Science and Technology Co., Ltd.;   Beijing Cancer Hospital
    Not yet recruiting
  • Study of Anti-CD19/CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
    NCT03824964
    Condition:   Refractory B-Cell Lymphoma
    Intervention:   Biological: Anti-CD19/CD22 CAR NK Cells
    Sponsors:   Allife Medical Science and Technology Co., Ltd.;   Beijing Cancer Hospital
    Not yet recruiting
  • Study of Anti-CD22 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
    NCT03692767
    Condition:   Refractory B-Cell Lymphoma
    Intervention:   Biological: Anti-CD22 CAR NK Cells
    Sponsor:   Allife Medical Science and Technology Co., Ltd.
    Not yet recruiting
  • Study of Anti-CD19 CAR NK Cells in Relapsed and Refractory B Cell Lymphoma
    NCT03690310
    Condition:   Refractory B-Cell Lymphoma
    Intervention:   Biological: Anti-CD19 CAR NK Cells
    Sponsor:   Allife Medical Science and Technology Co., Ltd.
    Not yet recruiting
  • Trial of R-GemOx Versus R-miniCHOP Regimen in First-line Treatment of Elderly Diffuse Large B Cell Lymphoma
    NCT02767674
    Condition:   Diffuse Large B Cell Lymphoma
    Interventions:   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Cyclophosphamide;   Drug: Epirubicin Injectable Product;   Drug: Vindesine;   Drug: Prednisone
    Sponsor:   The First Affiliated Hospital with Nanjing Medical University
    Recruiting
  • Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)
    NCT04148742
    Condition:   Non-Hodgkin's B-cell Lymphoma
    Intervention:   Drug: DZD9008
    Sponsor:   Dizal (Jiangsu) Pharmaceutical Co., Ltd.
    Not yet recruiting
  • Chidamide Combined With VDDT Regimen in the Relapse and Refractory Diffuse Large B Cell Lymphoma
    NCT02733380
    Condition:   Diffuse Large B-cell Lymphoma
    Interventions:   Drug: Chidamide;   Drug: Vinorelbine;   Drug: Liposomal Doxorubicin or mitoxantrone;   Drug: Dexamethasone;   Drug: Thalidomide
    Sponsor:   Henan Cancer Hospital
    Recruiting
  • Study of Tisagenlecleucel in Combination With Pembrolizumab in r/r Diffuse Large B-cell Lymphoma Patients
    NCT03630159
    Condition:   Diffuse Large B-cell Lymphoma
    Interventions:   Biological: Tisagenlecleucel;   Drug: Pembrolizumab
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients
    NCT03876028
    Condition:   Diffuse Large B-cell Lymphoma
    Interventions:   Biological: Tisagenlecleucel;   Drug: Ibrutinib
    Sponsor:   Novartis Pharmaceuticals
    Recruiting
  • Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma
    NCT03704298
    Condition:   Refractory Large B-cell Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Axicabtagene Ciloleucel;   Biological: Utomilumab
    Sponsors:   Kite, A Gilead Company;   Pfizer
    Recruiting
  • Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Either Rituximab or Lenalidomide in Participants With Refractory Large B-Cell Lymphoma (ZUMA-14)
    NCT04002401
    Condition:   Refractory Large B-cell Lymphoma
    Interventions:   Biological: Axicabtagene Ciloleucel;   Drug: Rituximab;   Drug: Lenalidomide;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Gilead Sciences
    Recruiting
  • CART-19 Cells for R/R B-cell Lymphoma
    NCT03391726
    Condition:   Relapsed or Refractory B-cell Lymphoma
    Intervention:   Other: CART-19 cells
    Sponsor:   Fujian Medical University
    Recruiting
  • Study of A-319 in Patients With Relapsed or Refractory B-cell Lymphoma
    NCT04056975
    Condition:   Relapsed or Refractory B-cell Lymphoma
    Intervention:   Biological: Recombinant Anti-CD19m-CD3 Antibody Injection
    Sponsors:   Generon (Shanghai) Corporation Ltd.;   Beijing Cancer Hospital
    Not yet recruiting
  • Treatment of Elderly Patients With Diffuse Large B-cell Lymphoma
    NCT03513601
    Condition:   Diffuse Large B Cell Lymphoma
    Interventions:   Drug: (R)-CHOP regimen;   Drug: (R)-CVP regimen
    Sponsor:   Mingzhi Zhang
    Recruiting
  • Design of New Personalized Therapeutic Approaches for Diffuse Large B-cell Lymphoma
    NCT03797170
    Condition:   Diffuse Large B Cell Lymphoma
    Intervention:   Other: Gut microbiota samples
    Sponsor:   University of Bologna
    Recruiting
  • Mature B-Cell Lymphoma And Leukemia Study III
    NCT01046825
    Condition:   Mature B-Cell Lymphoma
    Interventions:   Drug: COPAD;   Drug: COP, COPD M3, CYM;   Drug: COP, COPADM8, CYVE
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting
  • CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
    NCT04026100
    Condition:   Diffuse Large B-cell Lymphoma
    Intervention:   Biological: CTA101
    Sponsors:   The First Affiliated Hospital with Nanjing Medical University;   Nanjing Bioheng Biotech Co., Ltd.
    Not yet recruiting
  • Early Systemic Central Nervous System Prophylaxis in Diffuse Large B-cell Lymphoma
    NCT03719560
    Condition:   Diffuse Large B Cell Lymphoma
    Interventions:   Drug: Methotrexate;   Drug: Cytarabine
    Sponsor:   Brown University
    Not yet recruiting
  • Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma
    NCT03208556
    Condition:   Relapsed or Refractory B-cell Lymphoma
    Interventions:   Biological: iPD1 CD19 eCAR T cells;   Drug: Fludarabine and cyclophosphamide
    Sponsors:   Peking University;   Marino Biotechnology Co., Ltd.
    Recruiting
  • Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma
    NCT03576443
    Condition:   Diffuse Large B Cell Lymphoma
    Intervention:   Drug: Idelalisib
    Sponsor:   Nordic Lymphoma Group
    Recruiting
  • A Clinical Trial of Decitabine in Relapse and Refractory Diffuse Large B Cell Lymphoma
    NCT03579082
    Condition:   Diffuse Large B Cell Lymphoma
    Intervention:   Drug: Decitabine
    Sponsor:   Mingzhi Zhang
    Recruiting
  • A Study Comparing the Efficacy and Safety of G-CHOP Versus R-CHOP in Untreated Diffuse Large B-cell Lymphoma Patients
    NCT03650933
    Condition:   Diffuse Large B-Cell Lymphoma, Unspecified Site
    Interventions:   Biological: G-CHOP;   Biological: R-CHOP
    Sponsor:   Nanjing Yoko Biomedical Co., Ltd.
    Not yet recruiting
  • Dose-Reduced Consolidation Radiation Therapy in Patients With Diffuse Large B-cell Lymphoma
    NCT03681535
    Condition:   Diffuse Large B Cell Lymphoma
    Intervention:   Radiation: Radiation Therapy
    Sponsor:   Duke University
    Recruiting
  • Real Time Molecular Characterization of Diffuse Large B Cell Lymphoma (DLBCL)
    NCT03104478
    Condition:   Diffuse Large B Cell Lymphoma
    Intervention:   Procedure: Biological samples collection
    Sponsor:   The Lymphoma Academic Research Organisation
    Recruiting
  • A Study of CXD101 in Combination With Pembrolizumab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    NCT03873025
    Condition:   Diffuse Large B Cell Lymphoma
    Intervention:   Combination Product: Pembrolizumab and CXD101
    Sponsors:   University College, London;   Celleron Therapeutics Ltd.;   Merck Sharp & Dohme Corp.
    Not yet recruiting
  • A Trial to Evaluate the Efficacy and Safety of MOR208 With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    NCT02763319
    Condition:   Diffuse Large B-cell Lymphoma
    Interventions:   Drug: Rituximab (RTX);   Drug: MOR208;   Drug: Bendamustine (BEN)
    Sponsors:   MorphoSys AG;   ICON Clinical Research
    Recruiting
  • Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma
    NCT03399513
    Condition:   Diffuse Large B Cell Lymphoma
    Interventions:   Drug: Ibrutinib Oral Capsule [Imbruvica];   Drug: R-CHOEP chemotherapy
    Sponsors:   University Hospital Muenster;   Janssen-Cilag G.m.b.H
    Recruiting
  • A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
    NCT03688152
    Conditions:   Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: INCB053914;   Drug: INCB050465
    Sponsor:   Incyte Corporation
    Recruiting
  • Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
    NCT03777085
    Condition:   Diffuse Large B-cell Lymphoma
    Interventions:   Drug: TQB2303;   Drug: Rituximab
    Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Recruiting
  • A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    NCT04182204
    Condition:   Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Polatuzumab Vedotin;   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Oxaliplatin
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • 18F-FDG PET Scan and MRI Diffusion.Evaluation of the Early Therapeutic Response of Diffuse Large B-cell Lymphoma
    NCT03121456
    Condition:   Diffuse Large B Cell Lymphoma
    Interventions:   Other: 18F-FDG PET SCAN;   Other: MRI DIFFUSION
    Sponsor:   Centre Antoine Lacassagne
    Recruiting
  • A Study to Compare the Efficacy and Safety of JHL1101 Versus Rituximab in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL)
    NCT03670901
    Condition:   Diffuse Large B-Cell Lymphoma
    Interventions:   Biological: JHL1101;   Biological: MabThera
    Sponsor:   JHL Biotech, Inc.
    Not yet recruiting
  • Bendamustine Plus Subcutaneous Rituximab in Patients With Diffuse Large B-cell Lymphoma
    NCT02753062
    Condition:   Diffuse Large B Cell Lymphoma
    Intervention:   Drug: bendamustine, rituximab
    Sponsors:   Asan Medical Center;   Cheolwon Suh
    Recruiting
  • A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy
    NCT03677154
    Condition:   Diffuse Large B-cell Lymphoma
    Interventions:   Drug: Mosunetuzumab;   Drug: Tocilizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Study of TQB2450 Injection in Subjects With Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma
    NCT04002622
    Condition:   Relapsed or Refractory Primary Mediastinal B-cell Lymphoma (rrPMBCL)
    Intervention:   Drug: TQB2450
    Sponsor:   Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Recruiting
  • Efficacy of Consolidative Involved-site Radiotherapy for Patients With Limited-stage Diffuse Large B-cell Lymphoma
    NCT02449265
    Condition:   Diffuse Large B-cell Lymphoma
    Interventions:   Radiation: Consolidation involved-site radiotherapy (ISRT);   Radiation: Consolidation involved-field radiotherapy (IFRT);   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
    Sponsor:   Wuhan University
    Recruiting
  • A Study Comparing the Efficacy and Safety of Polatuzumab Vedotin With Rituximab-Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab-Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Diffuse Large B-Cell Lymphoma
    NCT03274492
    Condition:   Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Polatuzumab Vedotin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Vincristine Placebo;   Drug: Prednisone;   Drug: Polatuzumab vedotin Placebo
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • The Palliative Benefit of Involved-site Radiotherapy for Patients With Advanced-stage Diffuse Large B-cell Lymphoma
    NCT02449278
    Condition:   Diffuse Large B-cell Lymphoma
    Interventions:   Radiation: Consolidation involved-site radiotherapy (ISRT);   Radiation: Consolidation involved-field radiotherapy (IFRT);   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
    Sponsor:   Wuhan University
    Recruiting
  • Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to Autologous Stem Cell Transplantation
    NCT02692248
    Condition:   Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Ibrutinib;   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Dexamethasone
    Sponsors:   Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea;   Janssen-Cilag, S.A.
    Recruiting
  • Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    NCT03936153
    Condition:   Diffuse Large B-cell Lymphoma (DLBCL)
    Intervention:   Drug: abexinostat
    Sponsor:   Xynomic Pharmaceuticals, Inc.
    Not yet recruiting
  • KPT-330 Plus RICE for Relapsed/Refractory Aggressive B-Cell Lymphoma
    NCT02471911
    Condition:   Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: KPT-330;   Drug: Rituximab;   Drug: Etoposide;   Drug: Carboplatin;   Drug: Ifosfamide;   Drug: Dexamethasone
    Sponsors:   Weill Medical College of Cornell University;   Karyopharm Therapeutics Inc
    Recruiting
  • A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    NCT03992339
    Condition:   Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    Intervention:   Drug: ATG-010 60 mg, orally, twice weekly, each 4 week (28-day) a cycle
    Sponsor:   Antengene Corporation
    Not yet recruiting
  • A Phase I/II Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Rituximab in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    NCT02957019
    Condition:   Diffuse Large B-cell Lymphoma (DLBCL)
    Interventions:   Drug: L19-IL2 - Ph I;   Drug: L19-IL2 at RD - Ph II;   Drug: Rituximab
    Sponsor:   Philogen S.p.A.
    Recruiting
  • Tumor-Specific Clonotype, Metabolic Profile, and PET/CT in Predicting Chemotherapy Response in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
    NCT02405078
    Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Chemotherapy;   Procedure: Computed Tomography;   Drug: Fludeoxyglucose F-18;   Procedure: Positron Emission Tomography
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma
    NCT04163302
    Condition:   Lymphoma, B-Cell
    Intervention:   Biological: CD19-PD1-CART Cell
    Sponsor:   Chinese PLA General Hospital
    Recruiting
  • Clinical Trial to Evaluate CD19 CAR T (CT032) in Patients With Relapsed and/or Refractory Non-Hodgkin's B Cell Lymphoma
    NCT03994913
    Conditions:   Refractory B-Cell Non-Hodgkin Lymphoma;   Relapsed B-cell Non-Hodgkin Lymphoma
    Intervention:   Biological: CAR-CD19 T Cells
    Sponsors:   Carsgen Therapeutics, Ltd.;   First Affiliated Hospital of Zhejiang University;   RenJi Hospital
    Recruiting
  • Autologous TAC T Cells Targeting CD19 in R/R Large B-Cell Lymphoma
    NCT03880279
    Condition:   Lymphoma, B-Cell
    Intervention:   Biological: TAC01-CD19
    Sponsor:   Triumvira Immunologics, Inc.
    Not yet recruiting
  • Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
    NCT04161248
    Condition:   Lymphoma, B-Cell
    Interventions:   Drug: Venetoclax;   Drug: RiTUXimab Injection;   Drug: Rituximab SC;   Drug: Gemcitabine;   Drug: Dexamethasone;   Drug: Cisplatin
    Sponsors:   Canadian Cancer Trials Group;   Roche Pharma AG;   AbbVie
    Not yet recruiting
  • Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell Lymphoma
    NCT04173455
    Condition:   Lymphoma, B-Cell
    Intervention:   Drug: HZ-A-018
    Sponsors:   First Affiliated Hospital of Zhejiang University;   Hangzhou HeZheng Pharmaceutical Co., Ltd
    Recruiting
  • Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma
    NCT02443077
    Conditions:   Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type
    Interventions:   Procedure: Autologous Bone Marrow Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Etoposide;   Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Melphalan;   Other: Pharmacogenomic Study;   Other: Placebo Administration
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Indolent Non Follicular Lymphomas Prognostic Project
    NCT02904577
    Condition:   Indolent B-Cell Lymphomas
    Intervention:   Other: Any treatment, watch and wait policy included
    Sponsor:   Fondazione Italiana Linfomi ONLUS
    Recruiting
  • Improving the Outcome of High-risk Aggressive B-cell Lymphoma Patients With Nivolumab Maintenance Therapy
    NCT03569696
    Condition:   Lymphoma, B-Cell
    Intervention:   Biological: nivolumab
    Sponsor:   Meirav Kedmi MD
    Recruiting
  • Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma
    NCT02992834
    Condition:   Lymphoma, B Cell
    Interventions:   Biological: IL-2 pre-treated CD19 cells;   Biological: IL-7/IL-15 pre-treated CD19 cells
    Sponsor:   jiangjingting
    Not yet recruiting
  • Safety, Tolerability and PK of BTK Inhibitor DTRMWXHS-12 in Patients With B-Cell Lymphomas
    NCT02891590
    Conditions:   Chronic Lymphocytic Leukemia;   B-cell Lymphomas
    Intervention:   Drug: DTRMWXHS-12
    Sponsor:   Zhejiang DTRM Biopharma
    Recruiting
  • Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma
    NCT02474550
    Conditions:   Diffuse Large B Cell Lymphoma;   Neutropenia, Febrile
    Intervention:  
    Sponsor:   Ajou University School of Medicine
    Recruiting
  • Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents
    NCT03206671
    Condition:   Mature B-cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Rituximab window;   Drug: Additional doses of Rituximab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin hydrochloride;   Drug: Vindesine Sulfate;   Drug: Etoposide;   Drug: Ifosfamide;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Vincristine
    Sponsors:   University Hospital Muenster;   Deutsche Krebshilfe e.V., Bonn (Germany)
    Recruiting
  • A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma
    NCT03307746
    Condition:   B Cell Lymphoma
    Intervention:   Drug: Varlilumab
    Sponsors:   University Hospital Southampton NHS Foundation Trust;   University Hospital Plymouth NHS Trust;   The Christie NHS Foundation Trust;   Oxford University Hospitals NHS Trust;   Celldex Therapeutics;   Cancer Research UK
    Recruiting
  • Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell Lymphoma
    NCT03458546
    Condition:   Lymphoma, B-Cell
    Intervention:   Drug: Roflumilast
    Sponsor:   The University of Texas Health Science Center at San Antonio
    Recruiting
  • ctDNA and Metabolites in CSF as Early Biomarkers of Secondary CNS Involvement in Diffuse Large B-cell Lymphoma
    NCT04112238
    Conditions:   Diffuse Large B Cell Lymphoma;   Central Nervous System Metastasis
    Intervention:  
    Sponsors:   Herlev Hospital;   Weill Medical College of Cornell University
    Recruiting
  • A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
    NCT02600897
    Condition:   Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Lenalidomide;   Drug: Obinutuzumab;   Drug: Polatuzumab Vedotin;   Drug: Rituximab
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma
    NCT03837873
    Conditions:   Diffuse Large B Cell Lymphoma;   High-grade B-cell Lymphoma;   Transformed Lymphoma
    Interventions:   Drug: Rituximab;   Drug: Etoposide;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Dexamethasone;   Drug: Cyclophosphamide;   Drug: Lenalidomide;   Drug: Cisplatin;   Drug: Cytarabine
    Sponsor:   Institute of Hematology & Blood Diseases Hospital
    Recruiting
  • Study of Intratumoral Selicrelumab With Atezolizumab in Patients With Refractory or Relapsed B Cell Lymphoma
    NCT03892525
    Conditions:   Recurrent B-Cell Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Selicrelumab;   Drug: Atezolizumab
    Sponsors:   The Lymphoma Academic Research Organisation;   Roche Pharma AG
    Recruiting
  • Abexinostat and Ibrutinib in Diffuse Large B-cell Lymphoma and Mantle Cell Lymphoma
    NCT03939182
    Conditions:   Diffuse Large B-cell Lymphoma;   Mantle Cell Lymphoma
    Interventions:   Drug: Abexinostat;   Drug: Ibrutinib
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Janssen Scientific Affairs, LLC;   Xynomic Pharmaceuticals, Inc.
    Recruiting
  • An Observational Study on Evaluating the Efficacy and Safety of Preemptive Antiviral Therapy With Tenofovir in HBsAg-positive Patients With Diffuse Large B-cell Lymphoma Receiving Rituximab-CHOP Chemotherapy (SPEED Study)
    NCT02354846
    Condition:   B-cell Lymphoma
    Intervention:  
    Sponsor:   Yonsei University
    Recruiting
  • Rituximab Plus CHOP Chemotherapy for Diffuse Large B-cell Lymphoma
    NCT02660710
    Conditions:   Diffuse Large B-cell Lymphoma;   HIV
    Intervention:   Drug: R-CHOP
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   John E. Fogarty International Center (FIC);   National Institutes of Health (NIH);   National Cancer Institute (NCI)
    Recruiting
  • CD19 CAR-T Cell Therapy for Relapsed/Refractory B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia
    NCT03854994
    Conditions:   B Cell Lymphoma;   B-cell Acute Lymphoblastic Leukemia
    Intervention:   Biological: Anti-CD19 CAR-T Cells Injection
    Sponsors:   Yan'an Affiliated Hospital of Kunming Medical University;   KAEDI
    Recruiting
  • Exosomes and Immunotherapy in Non-Hodgkin B-cell Lymphomas
    NCT03985696
    Condition:   Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
    Intervention:   Other: blood sample
    Sponsor:   University Hospital, Limoges
    Recruiting
  • Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
    NCT02900716
    Conditions:   Chronic Lymphocytic Leukemia;   B-Cell Lymphoma
    Interventions:   Drug: DTRMWXHS-12;   Drug: DTRM-505;   Drug: DTRM-555
    Sponsor:   Zhejiang DTRM Biopharma
    Recruiting
  • A Phase I Study of AC0010 in Patients With CLL/ SLL, MCL, DLBCL and Other NHL
    NCT03060850
    Condition:   B-cell Lymphoma
    Intervention:   Drug: AC0010MA
    Sponsor:   Hangzhou ACEA Pharmaceutical Research Co., Ltd.
    Recruiting
  • Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
    NCT03281551
    Conditions:   B-cell Acute Lymphoblastic Leukemia;   B-cell Lymphoma
    Intervention:   Drug: PZ01 CAR-T cells
    Sponsors:   Pinze Lifetechnology Co. Ltd.;   Chinese Academy of Sciences;   Navy General Hospital, Beijing
    Recruiting
  • Impact of CD34+ Cell Dose on Progression-free Survival Following High-Dose Therapy and Autologous Stem Cell Transplantation for Relapsed and Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    NCT02570542
    Conditions:   Diffuse Large B-cell Lymphoma (DLBCL);   Relapsed Diffuse Large B-cell Lymphoma (DLBCL);   Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    Interventions:   Procedure: leukapheresis;   Drug: Plerixafor;   Drug: carmustine, etoposide, cytarabine, melphalan;   Procedure: Autologous Stem Cell Transplantation
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Columbia University;   NorthShore University HealthSystem;   University of Rochester;   Medical College of Wisconsin;   University of Nebraska;   Sanofi;   University Hospitals Seidman Cancer Center
    Recruiting
  • CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma
    NCT03881761
    Conditions:   B-Cell Lymphoma Stage I;   Refractory;   Relapsed
    Intervention:   Biological: CD19/CD20 bispecific CAR-T cells
    Sponsors:   Henan Cancer Hospital;   Henan Hualong Biotechnology Company
    Recruiting
  • Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2
    NCT03129828
    Condition:   Diffuse Large B Cell Lymphoma
    Intervention:   Drug: Ibrutinib and Bortezomib + R-CHOP
    Sponsors:   Prof. Dr. Clemens Schmitt;   Charite University, Berlin, Germany;   Janssen-Cilag Ltd.
    Recruiting
  • CD19/22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma
    NCT03287817
    Conditions:   Diffuse Large B Cell Lymphoma;   Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   DLBCL
    Intervention:   Biological: AUTO3
    Sponsor:   Autolus Limited
    Recruiting
  • In Situ Vaccine for Low-Grade Lymphoma: Combination of Intratumoral Flt3L and Poly-ICLC With Low-Dose Radiotherapy
    NCT01976585
    Condition:   Low-Grade B-cell Lymphoma
    Interventions:   Drug: rhuFlt3L/CDX-301;   Drug: Poly-ICLC
    Sponsors:   Joshua Brody;   Celldex Therapeutics
    Recruiting
  • Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs
    NCT03346642
    Condition:   Primary Mediastinal Large B-cell Lymphoma
    Interventions:   Drug: Decitabine;   Drug: GVD chemotherapy;   Drug: SHR-1210
    Sponsor:   Chinese PLA General Hospital
    Recruiting
  • Safety and Efficacy of Bendamustine, Gemcitabine, Rituximab, Nivolumab (BeGeRN) in Patients With r/r DLBCL
    NCT03259529
    Condition:   Diffuse Large B Cell Lymphoma
    Interventions:   Drug: Bendamustine hydrochloride;   Drug: Gemcitabine 500 mg;   Drug: Gemcitabine 700 mg;   Drug: Gemcitabine 1000 mg;   Drug: Nivolumab;   Drug: Rituximab
    Sponsor:   St. Petersburg State Pavlov Medical University
    Recruiting
  • Nanochip Technology in Monitoring Treatment Response and Detecting Relapse in Participants With Diffuse Large B-Cell Lymphoma
    NCT03656835
    Conditions:   Diffuse Large B-Cell Lymphoma;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High Grade B-Cell Lymphoma
    Intervention:   Procedure: Molecular Nanotechnology
    Sponsors:   Ohio State University Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Blinatumomab Consolidation Post Autologous Stem Cell Transplantation in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
    NCT03072771
    Condition:   Diffuse Large B Cell Lymphoma
    Interventions:   Drug: Blinatumomab;   Procedure: Autologous stem cell transplant;   Drug: Carmustine;   Drug: Etoposide;   Drug: Cytarabine;   Drug: Melphalan;   Procedure: Peripheral blood draws
    Sponsors:   Washington University School of Medicine;   Amgen
    Recruiting
  • A Study of Brentuximab Vedotin, Rituximab, and Dose Attenuated CHP in Elderly Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
    NCT02734771
    Condition:   Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Brentuximab vedotin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone
    Sponsors:   Patrick Reagan;   Seattle Genetics, Inc.
    Recruiting
  • Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL
    NCT03305445
    Conditions:   Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Ipilimumab;   Drug: Nivolumab
    Sponsors:   Icahn School of Medicine at Mount Sinai;   Bristol-Myers Squibb
    Recruiting
  • Assessment of Survival and Autonomy With Rituximab Plus Chemotherapy or Rituximab Plus Lenalidomide for Elderly Patients With Relapsed Diffuse Large B-cell Lymphoma
    NCT04113226
    Conditions:   Chemotherapy;   Diffuse Large B-Cell Lymphoma (DLBCL), Nos;   Elderly
    Interventions:   Drug: Rituximab;   Drug: Lenalidomide 20 MG;   Other: Comprehensive Geriatric Assessment (CGA);   Other: Activities of daily living (ADL) scale
    Sponsors:   Centre Hospitalier Universitaire, Amiens;   cimiez hospital Nice;   Institut Bergonié;   groupe hospitalier public sud de l'oise;   Henri Mondor University Hospital;   Centre Henri Becquerel;   Hôpital Charles Foix;   Saint-Louis Hospital, Paris, France
    Not yet recruiting
  • Treatment for Advanced B-Cell Lymphoma
    NCT01859819
    Conditions:   Diffuse Large Cell Lymphoma;   Burkitt's Lymphoma;   High Grade B-cell Lymphoma
    Interventions:   Drug: Rituximab;   Drug: IT Cytarabine
    Sponsor:   New York Medical College
    Recruiting
  • Lenalidomide Based Immunotherapy in the Treatment of DLBCL
    NCT03715296
    Condition:   Diffuse Large B Cell Lymphoma
    Intervention:   Drug: Lenalidomide 25mg
    Sponsor:   Ruijin Hospital
    Recruiting
  • Lenalidomide Monotherapy in R/R DLBCL
    NCT04150328
    Condition:   Diffuse Large B Cell Lymphoma
    Intervention:  
    Sponsor:   MorphoSys AG
    Recruiting
  • Study Evaluating the Safety and Efficacy of iR2 in Untreated and Unfit Elderly Patients With DLBCL
    NCT03949062
    Condition:   Diffuse Large B Cell Lymphoma
    Interventions:   Drug: Ibrutinib;   Drug: Lenalidomide;   Drug: Rituximab
    Sponsor:   Ruijin Hospital
    Recruiting
  • A Study of ABT-199 Plus Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
    NCT03136497
    Conditions:   Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: ABT-199;   Drug: Ibrutinib;   Drug: Rituximab
    Sponsors:   Hackensack Meridian Health;   Janssen Scientific Affairs, LLC;   Genentech, Inc.
    Recruiting
  • Molecular Monitoring With Circulating Tumor DNA and Nivolumab Maintenance
    NCT03311958
    Condition:   Diffuse Large B Cell Lymphoma
    Intervention:   Drug: Nivolumab, IV, 240 mg
    Sponsor:   Fox Chase Cancer Center
    Recruiting
  • Phase Ib Study to Assess Safety and Preliminary Efficacy of Tafasitamab or Tafasitamab Plus Lenalidomide in Addition to R-CHOP in Patients With Newly Diagnosed DLBCL
    NCT04134936
    Condition:   Diffuse Large B-cell Lymphoma
    Interventions:   Drug: Tafasitamab;   Drug: Tafasitamab plus Lenalidomide
    Sponsor:   MorphoSys AG
    Recruiting
  • Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)
    NCT03639181
    Condition:   B-cell Non-Hodgkin's Lymphoma
    Intervention:   Biological: GB226
    Sponsor:   Genor Biopharma Co., Ltd.
    Recruiting
  • Chidamide With R-CHOP Regimen for DLBCL Patients
    NCT03201471
    Condition:   Diffuse Large B Cell Lymphoma
    Intervention:   Drug: Chidamide + R-CHOP regimen
    Sponsor:   First Affiliated Hospital of Zhejiang University
    Recruiting
  • Study to Assess Enzastaurin + R-CHOP in Subjects With DLBCL With the Genomic Biomarker DGM1™
    NCT03263026
    Condition:   Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Enzastaurin Hydrochloride;   Other: R-CHOP + placebo
    Sponsor:   Denovo Biopharma LLC
    Recruiting
  • A Study of HMPL-523 in Patients With Relapsed or Refractory Mature B-cell Neoplasms
    NCT02857998
    Condition:   Mature B-cell Neoplasms
    Intervention:   Drug: HMPL-523
    Sponsor:   Hutchison Medipharma Limited
    Recruiting
  • A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma
    NCT03671018
    Condition:   B-cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Mosunetuzumab;   Drug: Polatuzumab vedotin;   Drug: Rituximab;   Drug: Bendamustine;   Drug: Tocilizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Reduced Chemotherapy in Low Risk DLBCL
    NCT02752815
    Condition:   Diffuse Large B-cell Lymphoma
    Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Epirubicin;   Drug: Vincristine;   Drug: Prednisone
    Sponsor:   Ruijin Hospital
    Recruiting
  • The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma
    NCT04169932
    Conditions:   Relapsed and Refractory B Cell Lymphoma;   Non-Hodgkin Lymphoma
    Intervention:   Biological: CD20 CAR-T
    Sponsor:   Shanghai Longyao Biotechnology Inc., Ltd.
    Recruiting
  • A Phase Ib/II Study Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With CHOP or CHP-Polatuzumab Vedotin in Participants With B-Cell Non-Hodgkin Lymphoma
    NCT03677141
    Condition:   B-cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Mosunetuzumab;   Drug: Polatuzumab Vedotin;   Drug: Rituxumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Drug: Tocilizumab
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Bortezomib Maintenance in High Risk DLBCL
    NCT01965977
    Condition:   Diffuse Large B Cell Lymphoma
    Intervention:   Drug: Bortezomib
    Sponsors:   Samsung Medical Center;   Janssen, LP
    Recruiting
  • Azacitidine and Rituximab-GDP Immunochemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    NCT03719989
    Conditions:   Diffuse Large B Cell Lymphoma;   Relapsed Non Hodgkin Lymphoma;   Refractory Non-Hodgkin Lymphoma
    Intervention:   Drug: azacitidine plus R-GDP
    Sponsor:   Seoul National University Hospital
    Not yet recruiting
  • Copanlisib Hydrochloride and Nivolumab in Treating Patients With Recurrent or Refractory Diffuse Large B-cell Lymphoma or Primary Mediastinal Large B-cell Lymphoma
    NCT03484819
    Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma
    Interventions:   Drug: Copanlisib;   Drug: Copanlisib Hydrochloride;   Biological: Nivolumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Study of Betalutin for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (LYMRIT-37-05)
    NCT02658968
    Conditions:   Relapsed, Diffuse Large B-cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
    Intervention:   Drug: Betalutin
    Sponsor:   Nordic Nanovector
    Recruiting
  • QUILT 3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
    NCT04052061
    Conditions:   Diffuse Large B Cell Lymphoma;   Large-cell Lymphoma;   Lymphoma, B-Cell;   Lymphoma
    Intervention:   Biological: CD19 t-haNK
    Sponsor:   NantKwest, Inc.
    Not yet recruiting
  • RICE-ibrutinib in Relapsed DLBCL
    NCT02955628
    Conditions:   Diffuse Large B Cell Lymphoma;   Diffuse Large B-Cell Lymphoma Recurrent
    Intervention:   Drug: Ibrutinib-RICE
    Sponsors:   Singapore General Hospital;   Janssen, LP
    Recruiting
  • Acalabrutinib With Rituximab and Lenalidomide in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
    NCT04094142
    Condition:   Non-hodgkin Lymphoma,B Cell
    Intervention:   Drug: Acalabrutinib
    Sponsor:   Seoul National University Hospital
    Recruiting
  • A Study of BI-1206 in Combination With Rituximab in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma
    NCT03571568
    Condition:   Indolent B-Cell Non-Hodgkin Lymphoma
    Intervention:   Biological: BI1206
    Sponsor:   BioInvent International AB
    Recruiting
  • Exploratory Study of CD19-targeted Chimeric Antigen Receptor T Cells(BZ019) for Relapsed and Refractory B-cell Lymphoma
    NCT04067414
    Conditions:   Diffuse Large B Cell Lymphoma;   High-grade B-cell Lymphoma;   Transformed Lymphoma;   Primary Mediastinal Large B Cell Lymphoma
    Intervention:   Biological: BZ019
    Sponsors:   Institute of Hematology & Blood Diseases Hospital;   Shanghai Cell Therapy Engineering Technology Research Center Group Co., Ltd.
    Recruiting
  • Molecular Imaging Using Radiolabeled Atezolizumab to Assess Atezolizumab Biodistribution in Lymphoma Patients
    NCT03850028
    Condition:   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
    Intervention:   Other: 89Zr-atezolizumab PET scans
    Sponsors:   University Medical Center Groningen;   VU University Medical Center;   Stichting Hemato-Oncologie voor Volwassenen Nederland;   Hoffmann-La Roche
    Recruiting
  • First-line Antibiotic Therapy for Early-stage HP(+) Gastric Pure DLBCL
    NCT02388581
    Condition:   Gastric Diffuse Large B-cell Lymphoma
    Intervention:   Drug: Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole
    Sponsors:   National Health Research Institutes, Taiwan;   National Taiwan University Hospital;   Mackay Memorial Hospital;   China Medical University Hospital;   Taichung Veterans General Hospital;   Changhua Christian Hospital;   National Cheng-Kung University Hospital;   Chang Gung Memorial Hospital;   Kaohsiung Medical University
    Recruiting
  • Rituximab and Pembrolizumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma
    NCT03401853
    Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Biological: Rituximab
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting
  • Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda
    NCT03864419
    Conditions:   Burkitt Lymphoma;   KSHV-associated Multicentric Castleman Disease;   Diffuse Large B-Cell Lymphoma
    Interventions:   Biological: Rituximab or Rituximab Hyaluronidase Human;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Methotrexate;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Prednisone;   Drug: Etoposide
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting
  • A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL
    NCT04049825
    Condition:   Relapsed or Refractory Diffuse Large B-cell Lymphoma
    Intervention:   Drug: OPB-111077
    Sponsor:   Otsuka Pharmaceutical Co., Ltd.
    Recruiting
  • PK,PD,Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Gemcitabine and Oxaliplatin for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma
    NCT03488251
    Conditions:   Non-hodgkin Lymphoma,B Cell;   Refractory Diffuse Large B-Cell Lymphoma;   Relapsed Diffuse Large B-Cell Lymphoma
    Intervention:   Drug: MT-3724
    Sponsor:   Molecular Templates, Inc.
    Recruiting
  • Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma
    NCT04002947
    Conditions:   Diffuse Large B-Cell Lymphoma;   Non Hodgkin's Lymphoma;   DLBCL;   NHL
    Interventions:   Drug: DA-EPOCH;   Biological: Rituximab;   Drug: CHOP;   Drug: Acalabrutinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 562 in Subjects With r/r Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, or Follicular Lymphoma
    NCT03571828
    Conditions:   Diffuse Large B-cell Lymphoma(DLBCL);   Mantle Cell Lymphoma (MCL);   Follicular Lymphoma (FL)
    Intervention:   Drug: AMG 562
    Sponsor:   Amgen
    Recruiting
  • Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)
    NCT03340766
    Condition:   Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)
    Interventions:   Drug: Blinatumomab;   Drug: Pembrolizumab
    Sponsors:   Amgen;   Merck Sharp & Dohme Corp.
    Recruiting
  • OPTIMAL>60 / DR. CHOP, Improvement of Therapy of Elderly Patients With CD20+ DLBCL Using Rituximab Optimized and Liposomal Vincristine
    NCT01478542
    Condition:   CD20+ Aggressive B-Cell Lymphoma
    Interventions:   Drug: Conventional Vincristine;   Drug: Liposomal Vincristine;   Drug: Ricover-scheme rituximab;   Drug: optimised rituximab-schedule
    Sponsors:   University Hospital, Saarland;   German High-Grade Non-Hodgkin's Lymphoma Study Group;   Spectrum Pharmaceuticals, Inc
    Recruiting
  • Study to Evaluate the Efficacy and Tolerability Debio 1562 in Combination With Rituximab in Patients With Relapsed and/or Refractory DLBCL and Other Forms of NHL
    NCT02564744
    Conditions:   Diffuse Large B-Cell Lymphoma;   B-cell Non-Hodgkin's Lymphoma
    Interventions:   Drug: Debio 1562;   Drug: Rituximab
    Sponsor:   Debiopharm International SA
    Recruiting
  • ENABLE (Engaging Toll-like Receptor Signalling for B-cell Lymphoma Chimeric Antigen Receptor Therapy)
    NCT04049513
    Conditions:   Lymphomas Non-Hodgkin's B-Cell;   Diffuse Large B-cell Lymphoma (DLBCL);   Primary Mediastinal B-cell Lymphoma (PMBCL);   Transformed Follicular Lymphoma (TFL);   Follicular Lymphoma (FL);   Mantle Cell Lymphoma (MCL)
    Interventions:   Biological: WZTL002-1 (1928T2z CAR-T cells);   Drug: Cyclophosphamide and Fludarabine lymphodepleting chemotherapy
    Sponsors:   Malaghan Institute of Medical Research;   Wellington Zhaotai Therapies Limited
    Recruiting
  • PK,PD, Safety and Tolerability of Multiple Dose Regimens of MT-3724 With Lenalidomide for the Treatment of Patients With Relapsed/Refractory Diffuse Large B Cell Non-Hodgkin's Lymphoma (MT-3724_NHL_003)
    NCT03645395
    Conditions:   Non-hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Relapsed Diffuse Large B-Cell Lymphoma
    Intervention:   Drug: MT-3724
    Sponsor:   Molecular Templates, Inc.
    Recruiting
  • Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL)
    NCT03990961
    Conditions:   Diffuse Large B Cell Lymphoma;   Lymphoma
    Intervention:   Drug: Pembrolizumab
    Sponsors:   University of Chicago;   Merck Sharp & Dohme Corp.
    Recruiting
  • A Study of RO7082859 in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas and Participants With DLBCL
    NCT03467373
    Conditions:   B-Cell Lymphoma;   Non-Hodgkin Lymphoma
    Interventions:   Drug: RO7082859;   Drug: Obinutuzumab (G);   Drug: Rituximab (R);   Drug: Tocilizumab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
    Sponsor:   Hoffmann-La Roche
    Recruiting
  • Ledipasvir+Sofosbuvir and Sofosbuvir+Velpatasvir for Pts With Indolent Bcell Lymphoma Associated With HCV Infection
    NCT02836925
    Conditions:   Indolent B-cell Lymphoma;   Hepatitis C
    Interventions:   Drug: Ledipasvir+Sofosbuvir;   Drug: Sofosbuvir+Velpatasvir
    Sponsor:   Fondazione Italiana Linfomi ONLUS
    Recruiting
  • Feasibility Study of Induction and Maintenance Avelumab Plus R-CHOP in Patients With Diffuse DLBCL: The AvR-CHOP Study
    NCT03244176
    Condition:   Lymphomas Non-Hodgkin's B-Cell
    Intervention:   Drug: Avelumab
    Sponsors:   Austin Health;   Merck KGaA, Darmstadt, Germany
    Recruiting
  • Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma
    NCT03223610
    Conditions:   Lymphoma;   Non-Hodgkin Lymphoma;   Diffuse Large B-Cell Lymphoma;   Burkitt Lymphoma
    Interventions:   Drug: Venetoclax;   Drug: Ibrutinib;   Drug: Prednisone;   Drug: Obinutuzumab;   Drug: Revlimid (lenalidomide)
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Tolerance and Pharmacokinetics of SHR1459 in Patients With Recurrent Replased/Refractory Mature B Cell Neoplasmstumor
    NCT03664297
    Condition:   Mature B Cell Neoplasms
    Intervention:   Drug: SHR1459
    Sponsor:   Jiangsu HengRui Medicine Co., Ltd.
    Recruiting
  • Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma
    NCT04156828
    Conditions:   Grade 3b Follicular Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Copanlisib;   Drug: Gemcitabine;   Drug: Carboplatin;   Drug: Dexamethasone;   Biological: Rituximab;   Biological: Pegfilgrastim
    Sponsors:   University of Washington;   National Cancer Institute (NCI);   Bayer
    Not yet recruiting
  • R2 and Combination Chemotherapy Versus R and Combination Chemotherapy in Newly Diagnosed Highly Aggressive B-NHL
    NCT04152577
    Condition:   Lymphoma, B-Cell
    Interventions:   Drug: R2-combination chemotherapy;   Drug: R-combination chemotherapy
    Sponsor:   Shandong Provincial Hospital
    Recruiting
  • Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose Therapy
    NCT03422523
    Conditions:   Diffuse Large B Cell Lymphoma;   Relapsed Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Atezolizumab;   Drug: Rituximab;   Drug: Gemcitabine 1000 mg;   Drug: Oxaliplatin 100 MG
    Sponsors:   University Hospital Southampton NHS Foundation Trust;   Hoffmann-La Roche
    Recruiting
  • Combination Chemotherapy and TAK-659 as Front-Line Treatment in Treating Patients With High-Risk Diffuse Large B Cell Lymphoma
    NCT03742258
    Conditions:   Diffuse Large B-Cell Lymphoma;   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Drug: Prednisone;   Biological: Rituximab;   Drug: Spleen Tyrosine Kinase Inhibitor TAK-659;   Drug: Vincristine Sulfate
    Sponsors:   Northwestern University;   National Cancer Institute (NCI)
    Recruiting
  • A PhaseⅠb Study Evaluating Safety and Efficacy of C-CAR011 Treatment in B- NHL Subjects
    NCT03483688
    Condition:   B-cell Non-Hodgkin Lymphoma
    Intervention:   Biological: CD19-directed CAR-T cells
    Sponsors:   Peking Union Medical College Hospital;   Cellular Biomedicine Group Ltd.
    Not yet recruiting
  • Marginal Zone Lymphoma Cohort in Korea
    NCT02732236
    Condition:   Lymphoma, B-Cell, Marginal Zone
    Intervention:   Other: Rituximab
    Sponsor:   Dong-A University Hospital
    Recruiting
  • Pembrolizumab in Relapsed and Refractory Gray-Zone Lymphoma (GZL), Primary Central Nervous System Lymphoma (PCNSL), and Other Extranodal Diffuse Large B-cell Lymphomas
    NCT03255018
    Conditions:   Non-Hodgkin Lymphoma;   Lymphoma;   Diffuse Large B-Cell Lymphoma;   Gray Zone Lymphoma;   Primary Central Nervious System Lymphoma
    Intervention:   Biological: Pembrolizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Mogamulizumab and Pembrolizumab in Treating Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
    NCT03309878
    Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent High Grade B-Cell Lymphoma;   Recurrent Transformed B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory High Grade B-Cell Lymphoma;   Refractory Transformed B-cell Non-Hodgkin Lymphoma
    Interventions:   Biological: Mogamulizumab;   Biological: Pembrolizumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • FT516 in Subjects With Advanced Hematologic Malignancies
    NCT04023071
    Conditions:   Acute Myelogenous Leukemia;   B-cell Lymphoma
    Interventions:   Drug: FT516;   Drug: Rituximab;   Drug: Obinutuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: IL-2
    Sponsor:   Fate Therapeutics
    Recruiting
  • Toripalimab in Combination With R-CHOP for Elderly Patients With Untreated Diffused B Cell Lymphoma
    NCT04058470
    Conditions:   Diffuse Large B Cell Lymphoma;   High-grade B-cell Lymphoma;   Follicular Lymphoma Grade IIIb;   Transformed Lymphoma;   EBV-Positive DLBCL, Nos;   ALK-Positive Anaplastic Large Cell Lymphoma
    Interventions:   Drug: Toripalimab;   Drug: R-CHOP Protocol
    Sponsor:   Huiqiang Huang
    Not yet recruiting
  • Safety and Antitumor Activity Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma
    NCT03684694
    Conditions:   Diffuse Large B-Cell Lymphoma;   Mantle Cell Lymphoma
    Intervention:   Drug: Loncastuximab Tesirine and Ibrutinib
    Sponsor:   ADC Therapeutics S.A.
    Recruiting
  • Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma
    NCT03939026
    Conditions:   Relapsed/Refractory Large B Cell Lymphoma;   Relapsed/Refractory Follicular Lymphoma
    Interventions:   Genetic: ALLO-501;   Biological: ALLO-647;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   Allogene Therapeutics
    Recruiting
  • Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell Lymphoma
    NCT01959698
    Conditions:   CD20 Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Stage I Diffuse Large B-Cell Lymphoma;   Stage II Diffuse Large B-Cell Lymphoma;   Stage III Diffuse Large B-Cell Lymphoma;   Stage IV Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Carboplatin;   Drug: Carfilzomib;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Biological: Rituximab
    Sponsors:   Roswell Park Cancer Institute;   National Cancer Institute (NCI);   Amgen
    Recruiting
  • Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients With Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma
    NCT03321643
    Conditions:   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma;   Richter Syndrome;   Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
    Interventions:   Drug: Atezolizumab;   Drug: Gemcitabine;   Other: Laboratory Biomarker Analysis;   Drug: Oxaliplatin;   Biological: Rituximab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
    NCT02633111
    Conditions:   B-cell Non-Hodgkin Lymphoma;   Aggressive
    Interventions:   Other: collected at pre-treatment tumor biopsy;   Other: Peripheral blood tests;   Device: PET/CT
    Sponsors:   Memorial Sloan Kettering Cancer Center;   Mayo Clinic;   M.D. Anderson Cancer Center;   University of Pennsylvania;   University of Miami
    Recruiting
  • A Phase II Study of the FIL on Elderly Frail Patients With DLBCL
    NCT02955823
    Condition:   Diffuse Large B-cells Non-Hodgkin Lymphoma
    Intervention:   Drug: Rituximab-Dexamethasone-Lenalidomide
    Sponsor:   Fondazione Italiana Linfomi ONLUS
    Recruiting
  • A Trial of Radiotherapy and Durvalumab in DLBCL and FL
    NCT03610061
    Conditions:   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma
    Interventions:   Drug: Durvalumab;   Radiation: Radiotherapy
    Sponsors:   Austin Health;   Olivia Newton-John Cancer Research Institute;   AstraZeneca
    Recruiting
  • A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
    NCT04045028
    Conditions:   Multiple Myeloma;   Non-Hodgkin Lymphoma;   B-Cell Lymphoma
    Interventions:   Drug: Tiragolumab;   Drug: Daratumumab;   Drug: Rituximab
    Sponsor:   Genentech, Inc.
    Recruiting
  • A National Study for Blood Based Response Monitoring of B-cell Lymphoma Patients
    NCT04139252
    Condition:   NHL
    Intervention:   Other: No intervention
    Sponsor:   Stichting Hemato-Oncologie voor Volwassenen Nederland
    Not yet recruiting
  • Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas
    NCT03161054
    Condition:   Aggressive Non-Hodgkin Lymphoma
    Interventions:   Drug: Prednisone;   Drug: Vinorelbine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Rituximab
    Sponsor:   Fondazione Italiana Linfomi ONLUS
    Recruiting
  • Sequential Infusion of Anti-CD19 and Anti-CD20 CAR-T Cells Against Relapsed and Refractory B-cell Lymphoma
    NCT03207178
    Condition:   Recurrent or Refractory B Cell Malignancy
    Intervention:   Biological: Mixed CD19/CD20 CAR-T Transfer
    Sponsors:   Shanghai Longyao Biotechnology Inc., Ltd.;   Xuzhou Medical University;   Shanghai Jiao Tong University School of Medicine
    Recruiting
  • Avelumab, Utomilumab, Rituximab, Ibrutinib, and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma
    NCT03440567
    Conditions:   CCND1 Positive;   CD20 Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mantle Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mantle Cell Lymphoma;   Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Avelumab;   Drug: Carboplatin;   Drug: Etoposide Phosphate;   Drug: Ibrutinib;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Biological: Rituximab;   Biological: Utomilumab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting
  • A Phase I Study of YY-20394 in Patients With B Cell Hematologic Malignancies
    NCT03757000
    Conditions:   B-cell Lymphoma Recurrent;   B-cell Chronic Lymphocytic Leukemia
    Intervention:   Drug: YY-20394
    Sponsor:   Shanghai YingLi Pharmaceutical Co. Ltd.
    Recruiting
  • R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma
    NCT02628405
    Conditions:   CD20 Positive;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma
    Interventions:   Drug: Carboplatin;   Drug: Etoposide;   Drug: Ifosfamide;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Biological: Rituximab
    Sponsors:   Academic and Community Cancer Research United;   National Cancer Institute (NCI)
    Recruiting
  • GEN3013 (DuoBody®-CD3xCD20) Safety Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma
    NCT03625037
    Conditions:   Diffuse Large B-cell Lymphoma;   High-grade B-cell Lymphoma;   Primary Mediastinal Large B-cell Lymphoma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Small Lymphocytic Lymphoma;   Marginal Zone Lymphoma
    Intervention:   Biological: GEN3013 (DuoBody®-CD3xCD20)
    Sponsor:   Genmab
    Recruiting
  • Thalidomide Combined With R-CHOP in Newly Diagnosed,Untreated Double-expressor Diffuse Large B-Cell Lymphoma Patients
    NCT03318835
    Condition:   Thalidomide
    Interventions:   Drug: Thalidomide combined with R-CHOP;   Drug: R-CHOP
    Sponsor:   Fudan University
    Recruiting
  • Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
    NCT03373019
    Conditions:   Chidamide;   Lymphoma, B-Cell;   Lymphoma, Large B-Cell, Diffuse;   Neoplasm by Histology;   Neoplasms;   Lymphoproliferative Disorders;   Lymphatic Diseases;   Immunoproliferative Disorders;   Immune System Diseases;   Lymphoma, Non-Hodgkin;   Cyclophosphamide;   Rituximab;   Gemcitabine;   Cisplatin;   Dexamethasone;   HDAC Inhibitor
    Intervention:   Drug: Chidamide combined with R-GDP
    Sponsor:   Fudan University
    Recruiting
  • MC-19PD1 CAR-T in Relapsed or Refractory B Cell Lymphoma
    NCT03932955
    Condition:   Lymphoma
    Intervention:   Biological: MC-19PD1 CAR-T cells
    Sponsor:   Peking University
    Recruiting
  • Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
    NCT03696784
    Conditions:   Lymphoma;   Lymphoma, B-Cell;   Immune System Diseases;   Immunoproliferative Disorders;   Lymphatic Diseases
    Interventions:   Biological: iC9-CAR19 T cells;   Drug: Bendamustine;   Drug: Fludarabine;   Drug: AP1903
    Sponsors:   UNC Lineberger Comprehensive Cancer Center;   Bellicum Pharmaceuticals;   V Foundation
    Recruiting
  • Tailored Prednisone Reduction in Preventing Hyperglycemia in Participants With B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment
    NCT03505762
    Condition:   B-Cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   Wake Forest University Health Sciences;   National Cancer Institute (NCI)
    Recruiting
  • Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma
    NCT03540303
    Condition:   Relapsed Non Hodgkin Lymphoma
    Intervention:   Drug: CAR19 T cells carrying cytoplasmic activated PD-1
    Sponsors:   Henan Cancer Hospital;   The Pregene (ShenZhen) Biotechnology Company, Ltd.
    Recruiting
  • CAR.CD19-CD28-zeta-2A-iCasp9-IL15-Transduced Cord Blood NK Cells, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Participants With B-cell Lymphoma
    NCT03579927
    Conditions:   CD19 Positive;   Mantle Cell Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma
    Interventions:   Procedure: Autologous Hematopoietic Stem Cell Transplantation;   Drug: Carmustine;   Drug: Cytarabine;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Melphalan;   Biological: Rituximab;   Biological: Umbilical Cord Blood-derived Natural Killer Cells
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Not yet recruiting
  • CD19 Targeted Chimeric Antigen Receptor T Cells for B Cell Lymphoma
    NCT03118180
    Condition:   Lymphoma
    Intervention:   Biological: CD19 targeted chimeric antigen receptor T cells
    Sponsors:   Zhejiang University;   Innovative Cellular Therapeutics Co., Ltd.
    Recruiting
  • Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
    NCT03964090
    Conditions:   Central Nervous System Lymphoma;   Secondary Central Nervous System Lymphoma
    Interventions:   Drug: TEDD-R;   Drug: TEDDI-R;   Drug: Ibrutinib;   Drug: Cytarabine;   Drug: Isavuconazole
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas
    NCT03038672
    Conditions:   ALK-Positive Large B-Cell Lymphoma;   Atypical Burkitt/Burkitt-Like Lymphoma;   Burkitt-Like Lymphoma With 11q Aberration;   Diffuse Large B-Cell Lymphoma Activated B-Cell Type;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   EBV-Positive Mucocutaneous Ulcer;   High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements;   High Grade B-Cell Lymphoma, Not Otherwise Specified;   Human Herpesvirus 8-Positive Neoplastic Cells Present;   Intravascular Large B-Cell Lymphoma;   Large B-Cell Lymphoma With IRF4 Rearrangement;   Plasmablastic Lymphoma;   Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type;   Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System;   Primary Effusion Lymphoma;   Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Recurrent B-Cell Non-Hodgkin Lymphoma;   Recurrent Burkitt Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Lymphomatoid Granulomatosis;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Refractory B-Cell Non-Hodgkin Lymphoma;   Refractory Burkitt Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Small Intestinal High Grade B-Cell Lymphoma, Not Otherwise Specified;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
    Interventions:   Biological: Nivolumab;   Drug: Varlilumab
    Sponsor:   National Cancer Institute (NCI)
    Recruiting
  • BI-1206 and an Anti-CD20 Antibody in Patients With CD32b Positive B-cell Lymphoma or Leukaemia
    NCT02933320
    Conditions:   B-cell Lymphoma;   Chronic Lymphocytic Leukaemia;   Waldenström Macroglobulinaemia
    Interventions:   Biological: BI-1206 single agent dose escalation phase;   Biological: BI-1206 single agent expansion phase;   Biological: Combination of BI-1206 with Rituximab
    Sponsor:   Cancer Research UK
    Recruiting
  • A Study of CPI-613 for Patients With Relapsed or Refractory Burkitt Lymphoma/Leukemia or High-Grade B-Cell Lymphoma With High-Risk Translocations
    NCT03793140
    Conditions:   Lymphoma;   Leukemia
    Intervention:   Drug: CPI-613
    Sponsors:   Memorial Sloan Kettering Cancer Center;   City of Hope Medical Center;   Massachusetts General Hospital;   M.D. Anderson Cancer Center;   George Washington University
    Recruiting
  • Sintilimab Plus R-CHOP as the First-line Treatment in Patients With Diffuse Large B-Cell Lymphoma.
    NCT04023916
    Conditions:   Diffuse Large B-Cell Lymphoma;   Sintilimab;   TP53 Mutation
    Intervention:   Drug: Sintilimab-R-CHOP
    Sponsor:   Chinese Academy of Medical Sciences
    Not yet recruiting
  • B001 in Patients With CD20 Positive B-cell Non Hodgkin's Lymphoma
    NCT03332121
    Condition:   CD20 Positive B Cell Non-Hodgkin's Lymphoma
    Intervention:   Biological: B001
    Sponsor:   Shanghai Pharmaceuticals Holding Co., Ltd
    Recruiting
  • Pembrolizumab and Vorinostat in Treating Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, or Hodgkin Lymphoma
    NCT03150329
    Conditions:   Grade 3b Follicular Lymphoma;   Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Recurrent Classic Hodgkin Lymphoma;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3a Follicular Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Transformed Non-Hodgkin Lymphoma;   Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma;   Refractory Classic Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Transformed Non-Hodgkin Lymphoma
    Interventions:   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab;   Drug: Vorinostat
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting
  • Study of ACTR707 in Combination With Rituximab in Subjects With Relapsed or Refractory B Cell Lymphoma
    NCT03189836
    Condition:   Lymphoma
    Interventions:   Biological: ACTR707;   Biological: rituximab
    Sponsor:   Unum Therapeutics Inc.
    Recruiting
  • A Combination of Acalabrutinib With R-CHOP for Patient Diffuse Large B-cell Lymphoma (DLBCL)
    NCT03571308
    Condition:   Non Hodgkin Lymphoma
    Intervention:   Drug: R-CHOP + acalabrutinib
    Sponsor:   University Hospital Southampton NHS Foundation Trust
    Recruiting
  • A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma
    NCT03758989
    Condition:   DLBCL
    Interventions:   Drug: Rituximab Prednisone;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
    Sponsor:   University of Rochester
    Recruiting
  • Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
    NCT02436707
    Condition:   Lymphoma
    Interventions:   Drug: Ibrutinib;   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Dexamethasone;   Drug: Cisplatin;   Drug: Mesna;   Drug: Cyclophosphamide;   Drug: Etoposide;   Drug: G-CSF
    Sponsors:   Canadian Cancer Trials Group;   Janssen, LP;   Roche Pharma AG
    Recruiting
  • Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas
    NCT02213913
    Conditions:   Adult Grade III Lymphomatoid Granulomatosis;   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   Contiguous Stage II Marginal Zone Lymphoma;   Contiguous Stage II Small Lymphocytic Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage II Small Lymphocytic Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Small Lymphocytic Lymphoma;   Testicular Lymphoma;   Untreated Hairy Cell Leukemia;   Waldenström Macroglobulinemia
    Interventions:   Drug: lenalidomide;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: rituximab;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis
    Sponsors:   University of Chicago;   National Cancer Institute (NCI)
    Recruiting
  • Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma
    NCT02494700
    Conditions:   Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage I Grade 1 Follicular Lymphoma;   Ann Arbor Stage I Grade 2 Follicular Lymphoma;   Ann Arbor Stage I Indolent Adult Non-Hodgkin Lymphoma;   Ann Arbor Stage I Mantle Cell Lymphoma;   Ann Arbor Stage II B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage II Grade 1 Follicular Lymphoma;   Ann Arbor Stage II Grade 2 Follicular Lymphoma;   Ann Arbor Stage II Indolent Adult Non-Hodgkin Lymphoma;   Ann Arbor Stage II Mantle Cell Lymphoma;   Ann Arbor Stage III B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage III Grade 1 Follicular Lymphoma;   Ann Arbor Stage III Grade 2 Follicular Lymphoma;   Ann Arbor Stage III Indolent Adult Non-Hodgkin Lymphoma;   Ann Arbor Stage III Mantle Cell Lymphoma;   Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Grade 1 Follicular Lymphoma;   Ann Arbor Stage IV Grade 2 Follicular Lymphoma;   Ann Arbor Stage IV Indolent Adult Non-Hodgkin Lymphoma;   Ann Arbor Stage IV Mantle Cell Lymphoma;   Ocular Adnexal Lymphoma;   Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma;   Orbit Lymphoma
    Interventions:   Radiation: External Beam Radiation Therapy;   Drug: Orbital Radiation
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting
  • Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse
    NCT03356054
    Condition:   DLBCL
    Interventions:   Combination Product: R-DHAP;   Drug: Brentuximab Vedotin
    Sponsor:   Stichting Hemato-Oncologie voor Volwassenen Nederland
    Not yet recruiting
  • Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
    NCT04007029
    Conditions:   CD19 Positive;   CD20 Positive;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Follicular Lymphoma;   Refractory Mantle Cell Lymphoma;   Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Small Lymphocytic Lymphoma
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Biological: Tocilizumab
    Sponsors:   Jonsson Comprehensive Cancer Center;   National Cancer Institute (NCI);   Parker Institute for Cancer Immunotherapy
    Recruiting
  • Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
    NCT03478514
    Conditions:   Mantle Cell Lymphoma;   B Cell Lymphoma
    Interventions:   Drug: Palbociclib;   Drug: Ibrutinib
    Sponsors:   Alliance Foundation Trials, LLC.;   Pfizer
    Recruiting
  • Phase I/II Study of SyB L-0501RI in Combination With Rituximab to Treat Lymphoma
    NCT03900377
    Condition:   Lymphoma, B-cell, Diffuse
    Intervention:   Drug: SyB L-0501RI
    Sponsor:   SymBio Pharmaceuticals
    Recruiting
  • Genomic Evaluation in Patients With Diffuse Large B Cell Lymphoma After First Relapse/Progression
    NCT03977623
    Condition:   Lymphoma, Large B-Cell, Diffuse
    Intervention:  
    Sponsor:   Samsung Medical Center
    Not yet recruiting
  • Human CD19 Targeted T Cells Injection(CD19 CAR-T) Therapy for Relapsed and Refractory CD19-positive Lymphoma.
    NCT03720457
    Conditions:   CD19-positive;   Diffuse Large B-cell Lymphoma;   Follicular Lymphoma
    Intervention:   Drug: Human CD19 targeted T Cells Injection
    Sponsors:   Hrain Biotechnology Co., Ltd.;   Shanghai Zhongshan Hospital
    Recruiting
  • Split-Dose R-CHOP for Older Adults With DLBCL
    NCT03943901
    Conditions:   Diffuse Large B Cell Lymphoma;   DLBCL;   Cancer
    Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone;   Biological: Pegfilgrastim
    Sponsors:   University of Wisconsin, Madison;   Medical College of Wisconsin
    Not yet recruiting
  • Lenalidomide Combined With R-CHOP(R2-CHOP) in Newly Diagnosed Double-expressor Diffuse Large B-Cell Lymphoma Patients
    NCT04164368
    Condition:   Double Expressor Lymphoma
    Intervention:   Drug: Lenalidomide combined with R-CHOP
    Sponsor:   Fudan University
    Recruiting
  • Interim FDG PET/CT in Diffuse Large B Cell Lymphoma (DLBCL) Patients
    NCT01357733
    Condition:   Lymphoma, Large B-Cell, Diffuse
    Intervention:   Other: Early interim FDG PET/CT after 1 cycle of R-CHOP
    Sponsor:   The Catholic University of Korea
    Recruiting
  • DPX-Survivac and Checkpoint Inhibitor in DLBCL
    NCT03349450
    Conditions:   Adult Diffuse Large Cell Lymphoma;   Recurrent;   Adult Refractory Diffuse Large B-Cell Lymphoma
    Interventions:   Biological: DPX-Survivac;   Biological: Pembrolizumab;   Drug: Cyclophosphamide 50mg
    Sponsors:   Sunnybrook Health Sciences Centre;   ImmunoVaccine Technologies, Inc. (IMV Inc.);   Merck Sharp & Dohme Corp.
    Recruiting
  • Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHL
    NCT03283137
    Conditions:   CLL;   B-cell Non Hodgkin Lymphoma
    Interventions:   Drug: TGR-1202;   Drug: Pembrolizumab
    Sponsor:   University of Chicago
    Recruiting
  • Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma
    NCT00670358
    Condition:   Lymphoma
    Interventions:   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: lenalidomide;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting
  • Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma
    NCT02871869
    Condition:   Diffuse, Large B-Cell, Lymphoma
    Interventions:   Drug: vindesine;   Drug: cyclophosphamide;   Drug: Epirubicin;   Drug: prednisone tablets;   Drug: Cinobufacini Tablets;   Drug: Rituximab
    Sponsor:   Xinjiang Medical University
    Recruiting
  • Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL
    NCT02362997
    Conditions:   Hodgkin Lymphoma;   Diffuse Large B Cell Lymphoma;   Peripheral T-Cell Lymphoma
    Intervention:   Drug: Pembrolizumab
    Sponsors:   Dana-Farber Cancer Institute;   Merck Sharp & Dohme Corp.
    Recruiting
  • Chidamide Combined With Clad/Gem/Bu With AutoSCT in R/R Diffuse Large B Cell Lymphoma
    NCT03151876
    Condition:   Lymphoma
    Interventions:   Drug: Chidamide;   Drug: Cladribine;   Drug: gemcitabine;   Drug: Busulfan;   Procedure: Autologous hematopoietic stem cell transplantation
    Sponsor:   Sichuan University
    Recruiting
  • Lenalidomide, Rituximab, Gemcitabine, Oxaliplatin and Dexamethasone in Relapse and Refractory DLBCL
    NCT03795571
    Conditions:   Diffuse Large B-cell Lymphoma Recurrent;   Diffuse Large B Cell Lymphoma Refractory
    Interventions:   Drug: Rituximab;   Drug: Gemcitabine;   Drug: Oxaliplatin;   Drug: Dexamethasone;   Drug: Lenalidomide Oral Capsule
    Sponsor:   The First Affiliated Hospital with Nanjing Medical University
    Recruiting
  • Study of TRPH-222 in Patients With Relapsed and/or Refractory B-Cell Lymphoma
    NCT03682796
    Conditions:   Lymphoma;   Lymphoma, B-Cell;   Lymphoma, Non-Hodgkin;   Lymphoma, Mantle-Cell;   Lymphoma, Marginal Zone;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular
    Intervention:   Drug: TRPH-222
    Sponsor:   Triphase Research and Development III Corp.
    Recruiting
  • R-CHOP Versus R-CDOP as First-line Treatment for Elderly Patients With Diffuse Large-B-cell Lymphoma
    NCT02428751
    Condition:   Lymphoma, Large B-Cell, Diffuse
    Interventions:   Drug: Pegylated liposomal doxorubicin;   Drug: Doxorubicin;   Drug: Rituximab;   Drug: Cyclophophamide;   Drug: Vincristine;   Drug: Prednisone
    Sponsor:   Wenqi Jiang
    Recruiting
  • BUCY+VP-16 vs BUCY Conditioning Regimen for DLBCL Undergoing Auto-HSCT
    NCT03229616
    Conditions:   Autologous Hematopoietic Stem Cell Transplantation;   Diffuse Large B-cell Lymphoma;   Conditioning
    Interventions:   Drug: Busulfan (BU);   Drug: Cyclophosphamide (CY);   Drug: Etoposide (VP-16)
    Sponsors:   Nanfang Hospital of Southern Medical University;   Guangzhou First People's Hospital;   Zhujiang Hospital;   Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University;   Third Affiliated Hospital, Sun Yat-Sen University;   Peking University People's Hospital
    Recruiting

Popular Now

  • Privacy Policy
  • Ad and Cookie Policy
  • Infringement Policy
  • Terms of Use
  • Email Policy
  • Contact Us
  • Post Clinical Trials
  • Join Clinical Trials
  • Volunteer Login
  • Recruiters Login
  • Frequently Asked Questions
  • Blog
  • Find Clinical Trials
  • Find Volunteers
  • Trials by Category
  • Trials by Location
  • Volunteers by Category
  • Volunteers by Location
All clinical trials are registered and certified with clinicaltrials.gov. Data via U.S. National Library of Medicine,U.S. National Institutes of Health, U.S. Department of Health & Human Services. JoinClinicaltrials.com (Aunica Media llc) is a free resource that provides individuals and companies with information regarding clinical trials that are being conducted nationwide. Aunica Media llc does not conduct clinical trials nor endorses them. Please consult your doctor or physician before participating. And Ye shall know the truth, and the truth shall make you free
©2001-2019 Aunica Media LLC